Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05556395 · ClinicalTrials.gov registry record

Global Blood-Brain Barrier Disruption and Post-Stroke Cognitive Decline

A clinical trial of Ischemic Stroke, sponsored by Johns Hopkins University.

Recruiting
Registry status
150
Enrollment target
1
Study location

NCT05556395: Recruiting study of Ischemic Stroke, sponsored by Johns Hopkins University.

NCT05556395 is a study of Ischemic Stroke that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 150 participants, below the 1,461-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05556395, a study of Ischemic Stroke, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
150 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to gain a better understanding of why some individuals who have suffered a stroke experience post-stroke cognitive decline. Specifically this study is testing whether global disruption of the blood-brain barrier detected at the time of the stroke is informative about the risk of post-stroke cognitive decline over the next 3 years.

Primary Outcome

Serial telephone-based cognitive assessments will be performed to detect cognitive changes (cognitive decline).

Conditions Studied

Study Locations (1)

Maryland

  • Johns Hopkins Hospital - Baltimore

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2022-04-01
Est. Completion 2027-04-01
Johns Hopkins University

1,448 total trials

What NCT05556395 shows while recruiting

NCT05556395 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 1,461-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (90% lower).

The record links to 1 condition, with Ischemic Stroke appearing as the primary indexed condition, and to 0 interventions.

NCT05556395 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT05556395 about?

NCT05556395 is a clinical study titled "Global Blood-Brain Barrier Disruption and Post-Stroke Cognitive Decline". The goal of this study is to gain a better understanding of why some individuals who have suffered a stroke experience post-stroke cognitive decline. Specifically this study is testing whether global disruption of the blood-brain barrier detected at the time of the stroke is informative about the ri...

What is the current status of trial NCT05556395?

This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2022-04-01. Estimated completion is 2027-04-01.

What conditions does trial NCT05556395 study?

This clinical trial studies the following conditions: Ischemic Stroke.

Who is sponsoring clinical trial NCT05556395?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05556395 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ischemic Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05556395's enrollment target sits among peer trials

150 26th of 66 higher than 40 of 66 other Ischemic Stroke trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ischemic Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05556395, the US trial registry maintained by the National Library of Medicine. NCT05556395 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.